Trastuzumab Deruxtecan Improves Survival vs Standard of Care for HER2-Low Metastatic Breast Cancer

Trastuzumab Deruxtecan Improves Survival vs Standard of Care for HER2-Low Metastatic Breast Cancer

header-info

Debra Patt, MD, PhD, MBA, Texas Oncology, US Oncology Network, discusses practice changing results from the DESTINY-Breast04 trial, which showed a 50% reduction in the risk of disease progression or death with trastuzumab deruxtecan vs standard chemotherapy for patients with HER2-low metastatic breast cancer.